NasdaqGM - Nasdaq Real Time Price USD

Lantheus Holdings, Inc. (LNTH)

Compare
110.05 +1.49 (+1.37%)
At close: September 20 at 4:00 PM EDT
110.05 0.00 (0.00%)
After hours: September 20 at 4:28 PM EDT
Loading Chart for LNTH
DELL
  • Previous Close 108.56
  • Open 108.74
  • Bid 109.81 x 600
  • Ask 110.35 x 800
  • Day's Range 107.61 - 110.47
  • 52 Week Range 50.20 - 126.89
  • Volume 984,922
  • Avg. Volume 1,079,874
  • Market Cap (intraday) 7.641B
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) 18.10
  • EPS (TTM) 6.08
  • Earnings Date Oct 31, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 144.55

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

www.lantheus.com

834

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LNTH

View More

Performance Overview: LNTH

Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LNTH
77.50%
S&P 500
19.55%

1-Year Return

LNTH
74.07%
S&P 500
28.32%

3-Year Return

LNTH
329.88%
S&P 500
28.64%

5-Year Return

LNTH
325.89%
S&P 500
89.66%

Compare To: LNTH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LNTH

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    7.65B

  • Enterprise Value

    7.51B

  • Trailing P/E

    18.11

  • Forward P/E

    1.48

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.39

  • Price/Book (mrq)

    7.45

  • Enterprise Value/Revenue

    5.22

  • Enterprise Value/EBITDA

    11.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    29.80%

  • Return on Assets (ttm)

    17.41%

  • Return on Equity (ttm)

    54.26%

  • Revenue (ttm)

    1.44B

  • Net Income Avi to Common (ttm)

    428.48M

  • Diluted EPS (ttm)

    6.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    757.02M

  • Total Debt/Equity (mrq)

    60.41%

  • Levered Free Cash Flow (ttm)

    263.3M

Research Analysis: LNTH

View More

Company Insights: LNTH

Research Reports: LNTH

View More

People Also Watch